𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease

✍ Scribed by Michael A. Rogawski; Gary L. Wenk


Book ID
109105625
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
519 KB
Volume
9
Category
Article
ISSN
1080-563X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


The place of memantine in the treatment
✍ Gill Livingston; Cornelius Katona πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 76 KB πŸ‘ 1 views

## Abstract ## Introduction Memantine is currently the only treatment approved for moderately severe to severe Alzheimer's disease (AD). There is still some discussion as to its place in clinical practice and many UK clinicians are discouraged for economic reasons from prescribing it. We adopt a β€˜

Use of vitamin C and E in the treatment
✍ SΓΆnke Arlt; Tomas MΓΌller-Thomsen; Ulrike Beisiegel πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 68 KB πŸ‘ 1 views

## Abstract Since it has become evident that increased oxidative stress is involved in the pathogenesis of Alzheimer's disease, the therapeutical use of antioxidants has been discussed. To date there are several studies showing that lipid peroxidation in particular is increased not only in brain ti

The NMDA receptor antagonist memantine a
✍ Wojciech Danysz; Chris G. Parsons πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 407 KB πŸ‘ 1 views

There is increasing evidence for the involvement of glutamate-mediated neurotoxicity in the pathogenesis of Alzheimer's disease (AD). We suggest that glutamate receptors of the N-methyl-D-aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner in this disorder. This continuous